capsules, provided by Douglas Laboratories®, contain 300 mg of
ipriflavone, a type of isoflavone. Isoflavones are one of many classes
of flavonoids, phytochemicals widely recognized and studied for their
numerous health benefits.
Ipriflavone may be a beneficial dietary
supplement for postmenopausal women, those at risk for osteoporosis, or
anyone concerned about bone health.
Ipriflavone helps promote
bone density by inhibiting bone resorption. Numerous studies of
postmenopausal women and individuals whose bones are showing signs of
demineralization have investigated the benefits of ipriflavone on bone
health. Laboratory and clinical studies have documented ipriflavone’s
positive effect on bone density. Experts agree that ipriflavone appears
to directly inhibit osteoclast activity, thereby decreasing bone
Osteoclasts and osteoblasts are two primary types
of bone cells. Osteoblasts, the more exterior cells, are responsible
for bone mineralization. Osteoclasts, found beneath the osteoblasts,
are responsible for bone resorption. When calcium levels in the blood
drop, the osteoblasts change shape, allowing the osteoclasts to become
exposed and release calcium from the bones to the rest of the body.
Scientists suspect ipriflavone may also stimulate osteoblast activity.
Since osteoblasts are responsible for laying down new bone, an increase
in osteoblast activity would result in increased bone mineralization.
This suggests Ipriflavone may not only inhibit the breakdown of
existing bone, but also encourage the formation of new bone.
is constantly turning over in a continuous process of formation and
resorption. During certain stages of life, the balance between bone
mineralization and resorption may be tipped. During childhood and
adolescence, while the body is growing, bone mineralization generally
exceeds bone resorption. Once one reaches peak bone mass, sometime
between the age of 20 and 30, bone formation slows down. For many, bone
resorption begins to prevail over bone formation, beginning the cycle
of progressive, age-associated bone demineralization. In women, bone
loss is generally accelerated following menopause. The decline in
estrogen levels associated with menopause appears to put women at
increased risk for declining bone density and osteoporosis.
affects a large proportion of postmenopausal women and the elderly in
developed countries. For some women, exogenous hormones provide some
continued protection against accelerated, progressive, postmenopausal
bone loss. Currently, there are few effective options for those women
who are unable to, or choose not to take hormone replacement therapy
(HRT). Ipriflavone, together with adequate calcium, vitamin D, and
other key nutrients in bone health, offers nonestrogenic protection
against excessive bone resorption. Unlike other well-known isoflavones,
such as genistein found in soy foods, ipriflavone does not have
estrogenic activity. Ipriflavone can be safely used in conjunction with
natural phytoestrogens or with HRT. Further, ipriflavone provides a
positive effect on bone health in women for whom hormone therapies are
Each capsule contains:
1 capsule twice daily as a dietary supplement, or as directed by a physician.
These statements have not been evaluated by the Food and Drug
Administration. These products are not intended to diagnose, treat
cure, or prevent any diseases.